Kilitch Drugs (India) Limited - Asset Resilience Ratio
Kilitch Drugs (India) Limited (KILITCH) has an Asset Resilience Ratio of 21.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Kilitch Drugs (India) Limited strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Kilitch Drugs (India) Limited's Asset Resilience Ratio has changed over time. See KILITCH net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Kilitch Drugs (India) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Kilitch Drugs (India) Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs330.90 Million | 8.3% |
| Short-term Investments | Rs539.23 Million | 13.53% |
| Total Liquid Assets | Rs870.13 Million | 21.83% |
Asset Resilience Insights
- Good Liquidity Position: Kilitch Drugs (India) Limited maintains a healthy 21.83% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kilitch Drugs (India) Limited Industry Peers by Asset Resilience Ratio
Compare Kilitch Drugs (India) Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Kilitch Drugs (India) Limited (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Kilitch Drugs (India) Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 16.77% | Rs524.66 Million ≈ $5.67 Million |
Rs3.13 Billion ≈ $33.83 Million |
-8.51pp |
| 2024-03-31 | 25.28% | Rs606.88 Million ≈ $6.56 Million |
Rs2.40 Billion ≈ $25.96 Million |
+7.30pp |
| 2023-03-31 | 17.98% | Rs394.65 Million ≈ $4.27 Million |
Rs2.20 Billion ≈ $23.74 Million |
-4.53pp |
| 2022-03-31 | 22.51% | Rs472.34 Million ≈ $5.11 Million |
Rs2.10 Billion ≈ $22.69 Million |
+4.59pp |
| 2021-03-31 | 17.92% | Rs364.00 Million ≈ $3.94 Million |
Rs2.03 Billion ≈ $21.97 Million |
-1.56pp |
| 2020-03-31 | 19.47% | Rs278.10 Million ≈ $3.01 Million |
Rs1.43 Billion ≈ $15.45 Million |
-0.31pp |
| 2019-03-31 | 19.78% | Rs284.16 Million ≈ $3.07 Million |
Rs1.44 Billion ≈ $15.54 Million |
-7.69pp |
| 2018-03-31 | 27.47% | Rs350.66 Million ≈ $3.79 Million |
Rs1.28 Billion ≈ $13.81 Million |
+2.37pp |
| 2017-03-31 | 25.09% | Rs283.30 Million ≈ $3.06 Million |
Rs1.13 Billion ≈ $12.21 Million |
+5.28pp |
| 2016-03-31 | 19.82% | Rs231.21 Million ≈ $2.50 Million |
Rs1.17 Billion ≈ $12.62 Million |
+0.35pp |
| 2015-03-31 | 19.47% | Rs246.69 Million ≈ $2.67 Million |
Rs1.27 Billion ≈ $13.71 Million |
-10.88pp |
| 2014-03-31 | 30.34% | Rs391.63 Million ≈ $4.24 Million |
Rs1.29 Billion ≈ $13.96 Million |
-48.77pp |
| 2013-03-31 | 79.11% | Rs1.08 Billion ≈ $11.71 Million |
Rs1.37 Billion ≈ $14.80 Million |
+1.34pp |
| 2012-03-31 | 77.77% | Rs1.38 Billion ≈ $14.88 Million |
Rs1.77 Billion ≈ $19.13 Million |
+77.77pp |
| 2011-03-31 | 0.00% | Rs25.00K ≈ $270.37 |
Rs1.61 Billion ≈ $17.44 Million |
-- |
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more